Lead Product Candidates


A key differentiator for Imunexus’ technology is the modular nature and the retrofitting capability of imunexinsTM that allows an unprecedented level of flexibility for generating multispecifics from existing antibodies and enzymes. Imunexus is currently focusing on converting marketed, clinically validated, or advanced preclinical antibodies and enzymes into multispecifics. This strategy carries key advantages over many other drug discovery and development approaches including:

  • The approach gives Imunexus a clear, risk-reduced path forward for creating therapeutic products based on a vast number of commercially validated, clinical, and preclinical antibodies and enzymes available.
  • Due to the ease of fusion and the lack of downstream engineering, the same imunexinTM modules can be “bolted on” to a number of different parent antibodies or enzymes (or other proteins) to rapidly (within months) generate extensive multispecific antibody pipelines.
  • Imunexus’ proprietary rapid-screen technology can identify new, target specific ImunexinsTM and convert existing antibodies and enzymes into bispecifics at a fraction of the cost of traditional bispecific drug discovery.
  • The development risks are lower and the clinical pathway is more predictable as the clinical properties of the parent biologic and its therapeutic target are well documented and supported with extensive preclinical and clinical data.


Imunexus’ has applied its unique technology to generate a number of therapeutic products. In the immediate term, Imunexus intends to advance the development of two pipeline products and one partner product as outlined below:

IMX101 - Bispecific Antibody Treatment for Small Cell Lung Cancer (SCLC). Imunexus will continue the development of a bispecific antibody treatment for SCLC. IMX101 is a multispecific antibody that utilizes an imunexinsTM that activates the immune system fused to a SCLC specific parent antibody. SCLC is an important disease and is classified as an unmet medical need due to sub-optimal current therapies and a poor prognosis resulting in a very low survival rate.

IMX113 - Bispecific Enzyme Treatment for a Rare Pediatric Disease. Imunexus is developing a bispecific enzyme treatment utilizing the Company's half-life extending imunexinsTM fused to an on-market enzyme replacement therapy used to treat a rare pediatric disease. The current treatment has a very short half-life of only minutes which requires frequent and prolonged administration via an intravenous canular in a health care setting. A longer half-life version of the existing treatment is predicted to improve how the drug is administered.

IMX39 Bispecific Enzyme Treatment for Multiple Sclerosis. Imunexus has partnered with The Baker Heart And Diabetes Institute to develop an exciting new treatment for a number of neurological diseases that affect the central nervous system with the primary focus on multiple sclerosis (MS). MS affects more than 2.8 million people worldwide and is 3 times more common in women than in men. MS is a chronic, autoimmune disease that attacks the central nervous system and causes damage to the protective sheath (known as myelin) that surrounds the nerves in the brain, spinal cord and optic nerves. This damage causes scars, or lesions, meaning that the nerves can’t send signals around the body properly. There is no known cure for MS.

Additional Pipeline Products: Along with the immediate term development of IMX101, IMX113 and IMX39, Imunexus plans are to continue to develop its other bispecific antibody products for the treatment of a number of oncology and autoimmune diseases.